Gadolinium Based Contrast Agents: Gadolinium Deposition Disease
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Gadolinium Based Contrast Agents (GBCAs) are substances that are injected into patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. However, as explained below, unfortunately some patients have experienced gadolinium side effects after these contrast agents were used for MRIs and MRAs.
There are two types of GBCAs: linear and macrocyclic. The macrocyclic GBCAs are generally regarded as “safer” than the linear GBCAs, as the structure makes it more difficult for the gadolinium to break away from its bonding agent.
Here are two lists of FDA-approved GBCA products:
|Magnevist||Bayer HealthCare Pharmaceuticals Inc.|
|Eovist||Bayer HealthCare Pharmaceuticals Inc.|
|MultiHance||Bracco Diagnostics Inc.|
|OptiMARK||Liebel-Flarsheim Company LLC|
|Ablavar||Lantheus Medical Imaging, Inc.|
|Gadavist||Bayer HealthCare Pharmaceuticals Inc.
Gadolinium Side Effects
When the toxic gadolinium contained in these substances breaks away from its bonding agent, it can be left behind in the bones, brain, and various tissues within the body. In turn, when this happens, there can be gadolinium side effects.
In more detail, this situation can lead to Gadolinium Deposition Disease (GDD) in patients, which is a form of gadolinium toxicity and sometimes called, instead, Gadolinium Storage Condition.
Symptoms of these gadolinium side effects can first appear anywhere from a few hours to several weeks after the MRI or MRA procedure when a GBCA injection was administered. Some of the more common symptoms reported by patients are:
- Persistent headache
- Severe pain in the bones, joints, arms, and legs
- Sensation of sharp pins and needles, cutting, or burning
- Cognitive impairment
- Clouded mentation (“brain fog”)
- Nausea / vomiting
- Thickening of soft-tissue, tendons, and ligaments
- Tightness in the hands and feet
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About This Drug
In May 2018 Health Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other gadolinium contrast injections for MRIs, CT scans, and other radiology procedures.
In May 2018 Health Canada issued this document, “Summary Safety Review – Gadolinium based contrast agents – Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects”. Therein, this drug safety regulatory agency for Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other radiology contrast agents containing gadolinium.
To read more of this article, click below:
From the Safety Review Findings part of that May 2018 Health Canada document we get these three points:
- This safety review looked at published and unpublished studies (57 in humans and 12 in animals) and 7 international case reports of gadolinium build-up in the brain linked to the use of GBCAs. The human studies and case reports found evidence of gadolinium build-up in the brain, in most cases this occurred many months after the use of GBCAs. Similar findings were seen in the animal studies.
- Evidence from these studies suggests that the risk of gadolinium build-up in the brain is higher with repeated use of GBCAs and with linear GBCAs. However, gadolinium build-ups were seen with both types of GBCAs.
- Factors that may increase the risk of gadolinium build-up in the brain following the use of GBCAs are not yet completely understood. However, patients who may need repeated GBCA use and vulnerable populations (e.g. children, pregnant women) may be more at risk of gadolinium build-up in the brain.
Our law firm is investigating possible products liability lawsuits against the pharmaceutical companies responsible for the linear gadolinium-based contrast agents, or contrast dyes, which are shown below:
- Magnevist — Bayer HealthCare Pharmaceuticals Inc.
- Eovist — Bayer HealthCare Pharmaceuticals Inc.
- MultiHance — Bracco Diagnostics Inc.
- Omniscan — GE Healthcare
- OptiMARK — Liebel-Flarsheim Company LLC
- Ablavar — Lantheus Medical Imaging, Inc.
If we can be of assistance to you or a loved one as regards a possible gadolinium contrast agents case, please do not hesitate to contact us.[Read article in full at original source]
Earlier articles by our firm:
- Gadolinium Retention Higher For Linear Agents Than Macrocyclic Agents
- MRI Contrast Agents: Gadolinium Retention Warnings Added To Drug Label
- Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More
- Gadolinium-Based Contrast Agents: Timeline of FDA Regulatory Actions
- Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures
- FDA And MHRA Actions For Gadolinium-Containing Contrast Agents Differ